Werfen completes acquisition of Immucor, Inc., expanding leadership in specialized diagnostics
In March this year, Werfen announced that it has successfully completed the acquisition of Immucor, Inc., after obtaining all necessary regulatory and antitrust approvals. Immucor is a privately held, US-based company, in the in vitro diagnostics (IVD) sector, with a solid global presence in the Transfusion and Transplant markets.
“During our more than 50-year history, we have demonstrated our strong commitment to expand our IVD business through organic growth, complemented with highly strategic acquisitions,” said Carlos Pascual, CEO of Werfen.
The price of the acquisition was approximately US$2 billion, financed by a combination of cash on-hand and bank debt facilities, syndicated by 19 national and international entities, led by BBVA, BNP Paribas, CaixaBank and HSBC. As part of its credit management, Werfen plans to refinance part of the debt in the capital markets, as well as quickly reduce the level of indebtedness. Following the announcement of the acquisition, Standard & Poor’s affirmed Werfen’s investment grade rating (BBB-) with a stable outlook.
With the integration of Immucor, Inc., Werfen expands its presence as a company of reference in the Specialized Diagnostics market and grows its portfolio of diagnostic solutions for hospitals and clinical laboratories. In addition, revenues will exceed €2.2 billion, and the Company will have seven technology centres and employ more than 7000 people worldwide with a direct presence in more than 30 countries and in more than 100 territories through distributors.
About Werfen
Founded in 1966, Werfen is a worldwide developer, manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company’s business lines include Hemostasis, Acute Care Diagnostics, Autoimmunity, and Original Equipment Manufacturing (OEM). Werfen operates directly in more than 30 countries and in more than 100 territories through distributors.
For more information, visit werfen.com.
About Immucor
Founded in 1982, Immucor is a global leader in Transfusion and Transplant diagnostics, facilitating patient–donor compatibility. The Company strives to create a world where anyone, anywhere in need of a transfusion or a transplant receives the right blood or transplant that is safe, accessible, and affordable. With the right match, a life can be transformed, together. To learn more, visit www.immucor.com.
Werfen’s portfolios
Werfen’s Hemostasis portfolio includes ACL TOP® Family 50 Series and ACL TOP Family Hemostasis Testing Systems, ACL AcuStar® system, ACL Elite® systems, HemoCell® Specialized Lab Automation, HemoHub® Intelligent Data Manager, along with the comprehensive line of HemosIL® assays.
The Acute Care portfolio includes the GEM® Premier™ 5000 system with Intelligent Quality Management 2 (iQM®2), GEM Premier 3500 system, GEM Premier ChemSTAT™ system, GEMweb® Plus Custom Connectivity, ROTEM® viscoelastic testing systems, Hemochron™ systems, VerifyNow™ platelet-function testing system, and Avoximeter™ CO-Oximeters.
The Autoimmunity portfolio includes Aptiva®, BIO-FLASH®, NOVA View, AUTOLoader and QUANTA-Lyser 3000 systems, and QUANTA Link data management solutions.
The Transfusion and Transplant portfolio includes the Echo Lumena®, Neo Iris®, Capture® Workstation systems, LIFECODES® assays, and ImmuLINK® Data Management solution.
